Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fish oil-Melbourne Health refers to a high-dose omega-3 polyunsaturated fatty acid supplementation regimen (6 g/day) evaluated by Melbourne Health in a Phase 4 clinical trial. The intervention consists of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are naturally derived small molecules classified as nutraceuticals. The study specifically investigated the efficacy of these supplements in preventing atrial mechanical stunning and structural remodeling in patients with persistent atrial fibrillation or atrial flutter following electrical cardioversion. Mechanistically, omega-3 fatty acids incorporate into cardiac cell membranes, where they exert anti-inflammatory, autonomic, and electrophysiological effects that may stabilize the atrial myocardium and reduce the recurrence of arrhythmias.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fish oil (Melbourne Health).